What is she best known for?
The fields of study she is best known for:
- Cancer
- Internal medicine
- Chemotherapy
The scientist’s investigation covers issues in Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Surgery.
Her research in Cancer, Chemotherapy, Phases of clinical research, Capecitabine and Lapatinib are components of Internal medicine.
The various areas that Véronique Diéras examines in her Oncology study include Adverse effect, Clinical endpoint, Estrogen receptor, Toxicity and Hazard ratio.
Her study in Breast cancer is interdisciplinary in nature, drawing from both Clinical trial and Metastasis.
Her Metastatic breast cancer research includes themes of Taxane, Aromatase inhibitor, Anthracycline, Vinorelbine and Bevacizumab.
In Surgery, she works on issues like Gastroenterology, which are connected to Meningeal carcinomatosis, Folinic acid, Breast carcinoma and Carcinoma.
Her most cited work include:
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer (2000 citations)
- Palbociclib and Letrozole in Advanced Breast Cancer (940 citations)
- 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (879 citations)
What are the main themes of her work throughout her whole career to date?
Her primary areas of study are Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Cancer.
Her Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Surgery.
Her research in Oncology intersects with topics in Neutropenia, Lapatinib, Capecitabine and Docetaxel.
Her work carried out in the field of Breast cancer brings together such families of science as Regimen, Adverse effect and Hazard ratio.
Her Metastatic breast cancer research focuses on Taxane and how it relates to Anthracycline.
She has researched Cancer in several fields, including Gynecology and Pathology.
She most often published in these fields:
- Internal medicine (81.84%)
- Oncology (64.33%)
- Breast cancer (46.61%)
What were the highlights of her more recent work (between 2018-2021)?
- Internal medicine (81.84%)
- Oncology (64.33%)
- Breast cancer (46.61%)
In recent papers she was focusing on the following fields of study:
Her primary areas of investigation include Internal medicine, Oncology, Breast cancer, Metastatic breast cancer and Cancer.
Her Internal medicine study typically links adjacent topics like Gastroenterology.
Her research in the fields of Overall survival overlaps with other disciplines such as In patient.
Her study on Palbociclib is often connected to Veliparib as part of broader study in Breast cancer.
Her Metastatic breast cancer research is multidisciplinary, incorporating elements of Taxane, Epidemiology, Capecitabine, Clinical endpoint and Cohort.
Her Chemotherapy study incorporates themes from Trastuzumab emtansine and Subgroup analysis.
Between 2018 and 2021, her most popular works were:
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial (203 citations)
- Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. (79 citations)
- Abstract GS1-04: IMpassion130: Efficacy in immune biomarker subgroups from the global, randomized, double-blind, placebo-controlled, phase III study of atezolizumab + nab-paclitaxel in patients with treatment-naïve, locally advanced or metastatic triple-negative breast cancer (46 citations)
In her most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
Véronique Diéras mainly investigates Internal medicine, Breast cancer, Oncology, Cancer and Metastatic breast cancer.
Her Gastroenterology research extends to the thematically linked field of Internal medicine.
Her work on Trastuzumab is typically connected to Veliparib as part of general Breast cancer study, connecting several disciplines of science.
The Oncology study combines topics in areas such as Carboplatin, Letrozole and Palbociclib.
Within one scientific family, she focuses on topics pertaining to Biomarker under Cancer, and may sometimes address concerns connected to Immunotherapy.
Her studies deal with areas such as Circulating tumor cell, Chemotherapy and Cohort as well as Metastatic breast cancer.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
